A source of information
that few know exists
Members get the change to define and prioritize the most pressing challenges we want to tackle, as well as influence how we tackle them. Among the critical challenges your peers want to address include:
Discussing the required clinical efficacy outcome for microbiome products vs classical therapeutics
Building investor confidence in microbiome drug development .
Navigating the unclear regulatory process for LBPs and harmonizing global regulatory affairs
Discovering translatability and consistency of pre-clinical models and how they adapt to microbiome products
Defining what a good model looks like whilst considering the risk and efficacy?
Ensuring what we’re developing has sufficient potency to have a clinically meaningful treatment effect to meet the regulatory endpoints
Understanding what the clinical endpoints of relevance are
The feedback from members speaks for itself…
Samantha Coulson, Head of Clinical Research, Servatus Biopharmaceuticals
“As leaders in the microbiome field with the goal to develop both safe and efficacious LBP drugs to meet the unmet needs of patients; we are all simultaneously facing our challenges. The most logical way to bring LBPs to market at an efficient pace is to share our experiences and knowledge whilst maintaining our Intellectual Property, that will accelerate benefits to the patient. And this is the opportunity I see that the Searchlight Network will provide.”
Karine Roget, Chief Scientific Officer, Nexbiome
“We can support one another in making meaningful progress by exchanging knowledge and offering guidance based on our own experiences. Being part of this Microbiome Drug Development Searchlight network means that we are more than willing to work collectively in this exciting and challenging fast-growing field.”
Trent Munro, Senior Vice President of Therapeutics, Microba
“My view is that the microbiome therapeutics sector is at a critical juncture as first-generation donor derived programs move into the clinical and cell bank derived consortia and single strain products move further down clinic translation. To help the sector address these challenges we require a central forum that can focus on the technical aspects of regulatory, CMC and clinical development. This searchlight network has the potential to be that essential forum for the microbiome industry”
For more reviews about Microbiome Drug Discovery: Searchlight membership, head to our testimonials page and hear directly from our members about why they've joined.
For more information on what’s included as part of the Microbiome Drug Development: Searchlight membership, please download the membership brochure.
Here’s what you’ll learn more about:
- The unique mission and purpose of the network
- What membership includes
- How the quarterly cornerstone meetings work
- How bespoke value delivery works
- How we deliver demonstrable value to you
- Annual member investment